With the majority of new gene therapies in 2022 being for neurological disorders, including the recent approvals of Skysona and Upstaza, it is clear that the future of gene therapy is in the CNS.
Because of this, companies are looking to expand their gene therapy portfolios or enter the neurological space, but drug developers face a significant number of hurdles currently preventing these therapies from reaching commercialisation, from poor translatability of preclinical models to clinical trial monitoring, delivery challenges and more.
As the gene therapy community gets a second wind, and as the clinical promise in neurology begins to be realised, now is the time to show drug developers how you can help them bring safe and efficacious gene therapies to market and form lasting partnerships with some of the leading biopharma in the space.
Experts Need Your Help With:
- Getting therapies across the blood brain barrier with high quality vectors adapted for cell selectivity and specificity
- Preclinical models not accurately representing how the drug interacts in a human brain
- Monitoring of clinical trials with biomarkers and endpoints
Meet your 2023 commercial objectives and educate decision-makers on how your expertise can deliver gene therapies to patients more effectively
Showcase your expertise to leading gene therapy organisations by securing an exhibition booth to set yourself as to go-to service provider in this community
Demonstrate thought leadership and drive brand exposure by securing a speaking slot on the agenda to connect with the community and generate partnerships
Maximize the balance of content and networking to generate leads and build new relationships with industry pioneers
Who Will You Meet?
To find out more how to elevate your brand, form meaningful relationships with KOLs, and capture new business with emerging companies in the CNS field, don’t hesitate to get in touch with us to find out more about how we can build a bespoke package to suit your 2023 business needs.